These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30956950)

  • 21. Targeting Oncogenic Mutant p53 for Cancer Therapy.
    Parrales A; Iwakuma T
    Front Oncol; 2015; 5():288. PubMed ID: 26732534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells.
    Nakazawa S; Sakata KI; Liang S; Yoshikawa K; Iizasa H; Tada M; Hamada JI; Kashiwazaki H; Kitagawa Y; Yamazaki Y
    Biomed Res; 2019; 40(1):37-49. PubMed ID: 30787262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties.
    Punganuru SR; Madala HR; Venugopal SN; Samala R; Mikelis C; Srivenugopal KS
    Eur J Med Chem; 2016 Jan; 107():233-44. PubMed ID: 26599530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53 as a hub in cellular redox regulation and therapeutic target in cancer.
    Eriksson SE; Ceder S; Bykov VJN; Wiman KG
    J Mol Cell Biol; 2019 Apr; 11(4):330-341. PubMed ID: 30892598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Salvation of the fallen angel: Reactivating mutant p53.
    Li Y; Wang Z; Chen Y; Petersen RB; Zheng L; Huang K
    Br J Pharmacol; 2019 Apr; 176(7):817-831. PubMed ID: 30632144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Role of p53 Signaling in Colorectal Cancer.
    Liebl MC; Hofmann TG
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33924934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PRIMA-1 and PRIMA-1
    Perdrix A; Najem A; Saussez S; Awada A; Journe F; Ghanem G; Krayem M
    Cancers (Basel); 2017 Dec; 9(12):. PubMed ID: 29258181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unraveling the Structural Changes in the DNA-Binding Region of Tumor Protein p53 (
    Balasundaram A; Doss CGP
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy.
    Bossi G; Sacchi A
    Head Neck; 2007 Mar; 29(3):272-84. PubMed ID: 17230559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells.
    Qiang W; Jin T; Yang Q; Liu W; Liu S; Ji M; He N; Chen C; Shi B; Hou P
    J Biomed Nanotechnol; 2014 Jul; 10(7):1249-58. PubMed ID: 24804545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
    Sigal A; Rotter V
    Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterogeneity of
    Monti P; Menichini P; Speciale A; Cutrona G; Fais F; Taiana E; Neri A; Bomben R; Gentile M; Gattei V; Ferrarini M; Morabito F; Fronza G
    Front Oncol; 2020; 10():593383. PubMed ID: 33194757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
    Selivanova G; Wiman KG
    Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reactivation of mutant p53 by capsaicin, the major constituent of peppers.
    Garufi A; Pistritto G; Cirone M; D'Orazi G
    J Exp Clin Cancer Res; 2016 Sep; 35(1):136. PubMed ID: 27599722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.
    Silva JL; Cino EA; Soares IN; Ferreira VF; A P de Oliveira G
    Acc Chem Res; 2018 Jan; 51(1):181-190. PubMed ID: 29260852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complexes formed by mutant p53 and their roles in breast cancer.
    Bellazzo A; Sicari D; Valentino E; Del Sal G; Collavin L
    Breast Cancer (Dove Med Press); 2018; 10():101-112. PubMed ID: 29950894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Follow the Mutations: Toward Class-Specific, Small-Molecule Reactivation of p53.
    Loh SN
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32075132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.
    Lindström MS; Jin A; Deisenroth C; White Wolf G; Zhang Y
    Mol Cell Biol; 2007 Feb; 27(3):1056-68. PubMed ID: 17116689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53: an overview of over two decades of study.
    Cheah PL; Looi LM
    Malays J Pathol; 2001 Jun; 23(1):9-16. PubMed ID: 16329542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thiosemicarbazones Functioning as Zinc Metallochaperones to Reactivate Mutant p53.
    Yu X; Blanden A; Tsang AT; Zaman S; Liu Y; Gilleran J; Bencivenga AF; Kimball SD; Loh SN; Carpizo DR
    Mol Pharmacol; 2017 Jun; 91(6):567-575. PubMed ID: 28320780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.